Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0NH5X
|
|||
Former ID |
DNC012240
|
|||
Drug Name |
2-(6-Cyclopentylamino-purin-9-yl)-ethanol
|
|||
Synonyms |
CHEMBL320370; 2-(6-Cyclopentylamino-purin-9-yl)-ethanol; BDBM50009691
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C12H17N5O
|
|||
Canonical SMILES |
C1CCC(C1)NC2=C3C(=NC=N2)N(C=N3)CCO
|
|||
InChI |
1S/C12H17N5O/c18-6-5-17-8-15-10-11(13-7-14-12(10)17)16-9-3-1-2-4-9/h7-9,18H,1-6H2,(H,13,14,16)
|
|||
InChIKey |
XVKHXAUTWLZBQD-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Adenosine A1 receptor (ADORA1) | Target Info | Inhibitor | [1] |
KEGG Pathway | cGMP-PKG signaling pathway | |||
cAMP signaling pathway | ||||
Sphingolipid signaling pathway | ||||
Neuroactive ligand-receptor interaction | ||||
Morphine addiction | ||||
NetPath Pathway | TCR Signaling Pathway | |||
RANKL Signaling Pathway | ||||
Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
Reactome | Adenosine P1 receptors | |||
G alpha (i) signalling events | ||||
WikiPathways | Nucleotide GPCRs | |||
GPCRs, Class A Rhodopsin-like | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. J Med Chem. 1991 Sep;34(9):2877-82. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.